Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies.

Lin RJ, Elko TA, Devlin SM, Shahrokni A, Jakubowski AA, Dahi PB, Perales MA, Tamari R, Shaffer BC, Sauter CS, Papadopoulos EB, Gyurkocza B, Korc-Grodzicki B, Barker JN, Maloy MA, Giralt SA.

Bone Marrow Transplant. 2019 Aug 30. doi: 10.1038/s41409-019-0654-6. [Epub ahead of print]

PMID:
31471572
2.

Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Bhatt V, Hilden P, Smith M, Thoren K, Cho C, Shah GL, Maloy MA, Papadopoulos EB, Jakubowski AA, Avecilla ST, O'Reilly RJ, Castro-Malaspina H, Tamari R, Shaffer BC, Boelens JJ, Perales MA, Giralt SA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1526-1535. doi: 10.1016/j.bbmt.2019.02.021. Epub 2019 Mar 1.

PMID:
30831208
3.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6.

PMID:
30625392
4.

Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Hsu M, Jakubowski AA, Shah GL, Cho C, Maloy MA, Avecilla ST, Papadopoulos EB, Gyurkocza B, Castro-Malaspina H, Tamari R, O'Reilly RJ, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1136-1141. doi: 10.1016/j.bbmt.2018.12.842. Epub 2019 Jan 6.

PMID:
30625387
5.

Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

Lin RJ, Hilden PD, Elko TA, Dahi PB, Shahrokni A, Jakubowski AA, Perales MA, Sauter CS, Castro-Malaspina HR, Barker JN, Shaffer BC, Tamari R, Papadopoulos EB, Maloy MA, Korc-Grodzicki B, Giralt SA.

Blood Adv. 2019 Jan 8;3(1):12-20. doi: 10.1182/bloodadvances.2018028241.

6.

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant.

Taur Y, Coyte K, Schluter J, Robilotti E, Figueroa C, Gjonbalaj M, Littmann ER, Ling L, Miller L, Gyaltshen Y, Fontana E, Morjaria S, Gyurkocza B, Perales MA, Castro-Malaspina H, Tamari R, Ponce D, Koehne G, Barker J, Jakubowski A, Papadopoulos E, Dahi P, Sauter C, Shaffer B, Young JW, Peled J, Meagher RC, Jenq RR, van den Brink MRM, Giralt SA, Pamer EG, Xavier JB.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaap9489. doi: 10.1126/scitranslmed.aap9489.

7.

Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.

Rondon-Clavo C, Scordo M, Hilden P, Shah GL, Cho C, Maloy MA, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Gyurkocza B, Castro-Malaspina H, Tamari R, Shaffer BC, Perales MA, Jaimes EA, Giralt SA.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2517-2522. doi: 10.1016/j.bbmt.2018.07.031. Epub 2018 Jul 26.

PMID:
30055353
8.

Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma.

Bryant AR, Perales MA, Tamari R, Peled JU, Giralt S.

Bone Marrow Transplant. 2018 Aug;53(8):1065-1068. doi: 10.1038/s41409-018-0142-4. Epub 2018 Mar 7. No abstract available.

PMID:
29515248
9.

Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.

Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, Hamadani M, Tamari R, Anderton K, Dixon P, Giralt SA.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1379-1385. doi: 10.1016/j.bbmt.2018.01.036. Epub 2018 Feb 2.

10.

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation.

Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2018 May;24(5):1079-1087. doi: 10.1016/j.bbmt.2018.01.001. Epub 2018 Jan 8.

11.

Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.

Cho C, Hsu M, Barba P, Maloy MA, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, Jakubowski AA, Koehne G, Meagher RC, O'Reilly RJ, Papadopoulos EB, Ponce DM, Tamari R, van den Brink MRM, Young JW, Devlin SM, Perales MA.

Bone Marrow Transplant. 2017 Dec;52(12):1629-1636. doi: 10.1038/bmt.2017.197. Epub 2017 Oct 9.

12.

Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.

Shah GL, Scordo M, Kosuri S, Herrera DA, Cho C, Devlin SM, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O'Reilly RJ, Jakubowski AA, Papadopoulos EB, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Perales MA, Giralt SA, Tamari R.

Biol Blood Marrow Transplant. 2018 Jan;24(1):142-149. doi: 10.1016/j.bbmt.2017.08.040. Epub 2017 Sep 22.

13.

Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Shah GL, Kosuri S, Herrera DA, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Avecilla ST, Meagher RC, Carlow DC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Tamari R, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Transplant. 2018 Jan;24(1):133-141. doi: 10.1016/j.bbmt.2017.08.033. Epub 2017 Sep 1.

14.

T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.

Jakubowski AA, Petrlik E, Maloy M, Hilden P, Papadopoulos E, Young JW, Boulad F, Castro-Malaspina H, Tamari R, Dahi PB, Goldberg J, Koehne G, Perales MA, Sauter CS, O'Reilly RJ, Giralt S.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1685-1694. doi: 10.1016/j.bbmt.2017.06.024. Epub 2017 Jul 19.

15.

The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.

Kosuri S, Adrianzen Herrera D, Scordo M, Shah GL, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Tamari R, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2017 Nov;23(11):2004-2011. doi: 10.1016/j.bbmt.2017.07.012. Epub 2017 Jul 18.

16.

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes.

Getta BM, Kishtagari A, Hilden P, Tallman MS, Maloy M, Gonzales P, Castro-Malaspina H, Perales MA, Giralt S, Tamari R, Klimek V.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1078-1086. doi: 10.1016/j.bbmt.2017.03.020. Epub 2017 Mar 20.

17.

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MR, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM.

Biol Blood Marrow Transplant. 2017 Mar;23(3):452-458. doi: 10.1016/j.bbmt.2016.12.633. Epub 2016 Dec 23.

18.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.

Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MRM, Young JW, O'Reilly RJ, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2017 Jan;23(1):67-74. doi: 10.1016/j.bbmt.2016.10.017. Epub 2016 Oct 24.

19.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V.

Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40. doi: 10.1016/j.bbmt.2015.10.005. Epub 2015 Oct 19.

20.

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.

Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1883-7. doi: 10.1016/j.bbmt.2015.09.005. Epub 2015 Sep 11. Review.

21.

Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact.

Lee YJ, Huang YT, Kim SJ, Maloy M, Tamari R, Giralt SA, Papadopoulos EB, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2016 Jan;22(1):174-8. doi: 10.1016/j.bbmt.2015.08.019. Epub 2015 Aug 28.

22.

High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, Dahi P, Hsu K, Jakubowski AA, Kernan NA, Koehne G, O'Reilly RJ, Papadopoulos EB, Perales MA, Sauter C, Scaradavou A, Tamari R, van den Brink MR, Young JW, Giralt S, Barker JN.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1985-93. doi: 10.1016/j.bbmt.2015.07.029. Epub 2015 Jul 31.

23.

CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales MA, Ponce DM, Sauter CS, Maloy MA, Herman DY, Klimek V, Young JW, O'Reilly RJ, Giralt SA, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2106-2114. doi: 10.1016/j.bbmt.2015.07.010. Epub 2015 Jul 14.

24.

Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R.

Bone Marrow Transplant. 2015 May;50(5):628-36. doi: 10.1038/bmt.2014.323. Epub 2015 Feb 9. Review.

25.

Transplant for MDS: challenges and emerging strategies.

Tamari R, Castro-Malaspina H.

Best Pract Res Clin Haematol. 2015 Mar;28(1):43-54. doi: 10.1016/j.beha.2014.11.006. Epub 2014 Dec 4. Review.

PMID:
25659729
26.

Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.

Tamari R, Castro-Malaspina H.

Curr Opin Hematol. 2015 Mar;22(2):184-90. doi: 10.1097/MOH.0000000000000121. Review.

PMID:
25635756
27.

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, Matasar MJ, Maragulia J, Giralt SA, Perales MA, Moskowitz CH, Sauter CS.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2004-9. doi: 10.1016/j.bbmt.2014.08.019. Epub 2014 Aug 28.

28.

Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.

Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A.

Leuk Lymphoma. 2014 Dec;55(12):2901-6. doi: 10.3109/10428194.2014.894186. Epub 2014 Mar 20.

PMID:
24650011
29.

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.

Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA.

Blood. 2013 Nov 7;122(19):3251-62. doi: 10.1182/blood-2013-04-498964. Epub 2013 Sep 6. Review.

30.

miR-21 mediates hematopoietic suppression in MDS by activating TGF-╬▓ signaling.

Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A.

Blood. 2013 Apr 11;121(15):2875-81. doi: 10.1182/blood-2011-12-397067. Epub 2013 Feb 6.

31.

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.

Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A.

Blood. 2012 Sep 6;120(10):2076-86. doi: 10.1182/blood-2011-12-399683. Epub 2012 Jul 2.

32.

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Blood. 2012 Jul 12;120(2):386-94. doi: 10.1182/blood-2011-12-399667. Epub 2012 May 24.

33.

Supplemental Content

Loading ...
Support Center